Inari Medical, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Director Robert Keith Warner reports the cancellation of Inari Medical shares and restricted stock units following the merger with Stryker Corporation, with shareholders receiving $80.00 per share.
Thomas Tu, Chief Medical Officer of Inari Medical, reports the cancellation and conversion of stock and options into cash following the merger with Stryker Corporation on February 19, 2025.
Director Catherine Szyman reports the disposition of Inari Medical shares and derivative securities following the merger with Stryker Corporation, where each share was converted to $80.00 in cash.
Form 4: Inari Medical CFO Kevin Strange Reports Beneficial Ownership Changes Following Stryker Merger
Following the merger of Inari Medical with Stryker Corporation, CFO Kevin Strange reports changes in his beneficial ownership of Inari Medical securities.
Karen Silva, Principal Accounting Officer of Inari Medical, reports the acquisition of Inari Medical by Stryker Corporation, resulting in the cancellation of her common stock and restricted stock units in exchange for $80 per share.
Form 4: Inari Medical Director Jonathan Root Reports Acquisition by Stryker, Cash-Out of Shares and RSUs
Director Jonathan Root reports the acquisition of Inari Medical by Stryker Corporation, resulting in the cash-out of his shares and restricted stock units (RSUs) at $80.00 per share.
Director Donald Milder reports the acquisition of Inari Medical by Stryker Corporation, with each share of common stock converted to $80 in cash.
Director Dana G. Mead Jr. reports the disposition of Inari Medical shares following the company's merger with Stryker Corporation, where each share was converted to $80.00 in cash.
Director Cynthia Lucchese reports the disposition of Inari Medical shares and derivative securities following the merger with Stryker Corporation, where each share was converted to $80.00 in cash.
Form 4: Inari Medical CEO Andrew Hykes Reports Beneficial Ownership Changes Following Stryker Merger
Andrew Hykes, CEO of Inari Medical, reports changes in beneficial ownership following the merger with Stryker Corporation, where Inari Medical became a wholly-owned subsidiary of Stryker.
Director William Hoffman reports changes in beneficial ownership of Inari Medical stock following the merger with Stryker Corporation, where each share was converted to $80.00 in cash.
Form 4: Inari Medical Director Rebecca Chambers Reports Disposition of Shares in Merger with Stryker
Director Rebecca Chambers reports the disposition of Inari Medical shares following the merger with Stryker Corporation, where each share was converted to $80.00 in cash.
Form 4: Inari Medical CEO Andrew Hykes Exercises Stock Options, Reports Beneficial Ownership Changes
Inari Medical's CEO, Andrew Hykes, executed stock options and reported changes in his beneficial ownership of the company's stock on February 10, 2025.
Thomas Tu, Chief Medical Officer of Inari Medical, exercised stock options at two different prices, resulting in the acquisition of 148,004 shares of common stock.
Inari Medical's CEO, Andrew Hykes, reports acquisition of restricted stock units and shares through the employee stock purchase plan, along with adjustments to indirect ownership.
Chief Financial Officer of Inari Medical, Kevin T. Strange, reports the acquisition of common stock through an employee stock purchase plan and the grant of restricted stock units.
Thomas Tu, Chief Medical Officer of Inari Medical, reports acquisition of restricted stock units and shares under the Employee Stock Purchase Plan.
Karen Silva, Principal Accounting Officer at Inari Medical, reports the acquisition of 5,504 shares of common stock and disposal of 14,719 shares.
Director William Hoffman of Inari Medical sold a total of 200,000 shares of common stock on January 6, 2025, under a pre-arranged 10b5-1 trading plan.
Andrew Hykes, President and CEO of Inari Medical, reports the disposal of shares to cover tax obligations related to vesting restricted share units.
Chief Financial Officer of Inari Medical, Kevin T. Strange, reports disposing of shares to cover tax obligations related to vesting restricted share units.
Thomas Tu, Chief Medical Officer of Inari Medical, reports disposing of shares to cover tax obligations related to vesting restricted share units.
Director William Hoffman of Inari Medical, Inc. reports disposing of shares to cover tax obligations related to vesting restricted share units.
Inari Medical's CEO, Andrew Hykes, sold 3,000 shares of common stock on December 20, 2024, under a pre-arranged 10b5-1 trading plan.
Director William Hoffman of Inari Medical sold a total of 59,610 shares of common stock on December 16, 2024, under a pre-arranged 10b5-1 trading plan.
Inari Medical's Chief Medical Officer, Thomas Tu, sold 4,000 shares of common stock at $55 per share on December 10, 2024, under a pre-arranged 10b5-1 trading plan.
Inari Medical's Principal Accounting Officer, Karen Silva, was granted 9,215 restricted stock units (RSUs) that will vest quarterly starting January 1, 2025.
Inari Medical's CEO, Andrew Hykes, sold 3,000 shares of common stock at $50.83 per share on November 20, 2024, under a pre-arranged 10b5-1 trading plan.
Director William Hoffman of Inari Medical sold a total of 60,000 shares of common stock on November 18, 2024, under a pre-arranged 10b5-1 trading plan.
Inari Medical's CEO, Andrew Hykes, sold 3,000 shares of common stock at $50 per share under a pre-arranged 10b5-1 trading plan.